JP2019532054A - Ｔｒｐｖ４拮抗薬 - Google Patents

Ｔｒｐｖ４拮抗薬 Download PDF

Info

Publication number
JP2019532054A
JP2019532054A JP2019515545A JP2019515545A JP2019532054A JP 2019532054 A JP2019532054 A JP 2019532054A JP 2019515545 A JP2019515545 A JP 2019515545A JP 2019515545 A JP2019515545 A JP 2019515545A JP 2019532054 A JP2019532054 A JP 2019532054A
Authority
JP
Japan
Prior art keywords
alkyl
substituted
fluoro
pharmaceutically acceptable
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019515545A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532054A5 (enExample
Inventor
エドワード、ジェイ、ブルナルディク
カール、エイ．ブルックス
ブライアン、ダブリュ、ブドゥジック
ブライアン、グリフィン、ロウホーン
ジェイ、エム．マシューズ
ジョン、ジェフリー、マカティー
ジョセフ、イー．ペロ
デイビッド、ジェイ．ベーム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of JP2019532054A publication Critical patent/JP2019532054A/ja
Publication of JP2019532054A5 publication Critical patent/JP2019532054A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2019515545A 2016-09-20 2017-09-20 Ｔｒｐｖ４拮抗薬 Pending JP2019532054A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662397013P 2016-09-20 2016-09-20
US62/397,013 2016-09-20
US201762482307P 2017-04-06 2017-04-06
US62/482,307 2017-04-06
PCT/IB2017/055703 WO2018055527A1 (en) 2016-09-20 2017-09-20 Trpv4 antagonists

Publications (2)

Publication Number Publication Date
JP2019532054A true JP2019532054A (ja) 2019-11-07
JP2019532054A5 JP2019532054A5 (enExample) 2021-02-12

Family

ID=60117716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019515545A Pending JP2019532054A (ja) 2016-09-20 2017-09-20 Ｔｒｐｖ４拮抗薬

Country Status (4)

Country Link
US (1) US10590077B2 (enExample)
EP (1) EP3515889A1 (enExample)
JP (1) JP2019532054A (enExample)
WO (1) WO2018055527A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7106528B2 (ja) 2016-09-20 2022-07-26 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド Ｔｒｐｖ４拮抗薬
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
TWI878266B (zh) 2019-02-15 2025-04-01 愛爾蘭商博士倫愛爾蘭有限公司 治療眼表痛之方法
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
US20230339934A1 (en) 2020-04-30 2023-10-26 Raqualia Pharma Inc. Pyrimidin-4(3h)-one derivatives as trpv4 antagonists
WO2021233752A1 (en) 2020-05-19 2021-11-25 Bayer Aktiengesellschaft Trpa1 antagonists for the treatment of diseases associated with pain and inflammation
EP4178982A1 (en) 2020-07-13 2023-05-17 Precirix N.V. Antibody fragment against folr1
TW202216143A (zh) 2020-07-16 2022-05-01 日商拉夸里亞創藥股份有限公司 作為眼疾病的治療藥之ｔｒｐｖ４抑制藥
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515984A (ja) * 2005-11-15 2009-04-16 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なアザインダゾール
JP2009523176A (ja) * 2006-01-11 2009-06-18 スミスクライン・ビーチャム・コーポレイション 新規化合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
IT1203660B (it) 1982-10-08 1989-02-15 Glaxo Group Ltd Dispositivi per somministrare farmaci a pazienti e confezione di blister per essi
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2178965B (en) 1985-07-30 1988-08-03 Glaxo Group Ltd Devices for administering medicaments to patients
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
HU213221B (en) 1990-03-02 1997-03-28 Glaxo Group Ltd Inhalation device and medicine packet for device
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
CN1232451A (zh) 1996-08-28 1999-10-20 普罗克特和甘保尔公司 取代的环状胺金属蛋白酶抑制剂
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
DK1461315T3 (da) 2001-12-06 2009-11-16 Cornell Res Foundation Inc Katalytisk carbonylering af tre- og fireleddede heterocykler
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
JP4969238B2 (ja) 2003-03-27 2012-07-04 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
KR101105909B1 (ko) 2004-02-16 2012-01-17 글락소 그룹 리미티드 약품 분배기에 사용되는 카운터
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
EP1755603A4 (en) 2004-04-28 2009-03-11 Merck & Co Inc 3,3-DISUBSTITUTED TETRAHYDROPYRANYL CYCLOPENTYL AMIDE MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY
EP1758884A2 (en) 2004-05-20 2007-03-07 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
CN1329374C (zh) 2004-06-09 2007-08-01 上海靶点药物有限公司 作为ccr5拮抗剂的化合物
KR20070041742A (ko) 2004-07-12 2007-04-19 바이엘 크롭사이언스 아게 살진균제 및 살충제로서의 치환된 2-피롤리돈 유도체
GB0418278D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Medicament dispenser
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
JP2009521451A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用な置換アニリン誘導体
US7884107B2 (en) 2006-06-30 2011-02-08 Merck Substituted piperidines that increase P53 activity and the uses thereof
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
US20110046199A1 (en) 2008-01-17 2011-02-24 Purdue Research Foundation Small molecule inhibitors of hiv proteases
CN102203074A (zh) 2008-06-20 2011-09-28 麦它波莱克斯股份有限公司 芳基gpr119激动剂及其用途
ES2605856T3 (es) 2012-11-16 2017-03-16 Bristol-Myers Squibb Company Moduladores GPR40 de dihidropirazol
TW201524952A (zh) 2013-03-15 2015-07-01 Araxes Pharma Llc Ｋｒａｓ ｇ１２ｃ之共價抑制劑
CA2900888A1 (en) 2013-03-15 2014-09-18 AbbVie Deutschland GmbH & Co. KG Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2014163161A1 (ja) 2013-04-04 2014-10-09 武田薬品工業株式会社 複素環化合物
WO2016016370A1 (en) 2014-07-31 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists
JP7106528B2 (ja) 2016-09-20 2022-07-26 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド Ｔｒｐｖ４拮抗薬
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515984A (ja) * 2005-11-15 2009-04-16 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なアザインダゾール
JP2009523176A (ja) * 2006-01-11 2009-06-18 スミスクライン・ビーチャム・コーポレイション 新規化合物

Also Published As

Publication number Publication date
EP3515889A1 (en) 2019-07-31
US10590077B2 (en) 2020-03-17
WO2018055527A1 (en) 2018-03-29
US20190202784A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
JP7025414B2 (ja) Ｔｒｐｖ４拮抗薬
JP2019532054A (ja) Ｔｒｐｖ４拮抗薬
JP7106528B2 (ja) Ｔｒｐｖ４拮抗薬
JP7110197B2 (ja) Ｎｒｆ２アクチベーター
JP2018517732A (ja) Ｎｒｆ２レギュレーター
EP3555088A1 (en) Bisaryl amides as nrf2 regulators
JP2020502123A (ja) Ｎｒｆ２アクチベーターとしてのビスアリール複素環
JP2018529744A (ja) Ｎｒｆ２レギュレーターとしてのアリールシクロヘキシルピラゾール
JP2020502129A (ja) Ｎｒｆ２アクチベーターとしての３−オキソ−１，４−ジアゼピニル化合物
JP2020500918A (ja) Ｎｒｆ２レギュレーターとしてのｎ−アリールピラゾール
JP2021524469A (ja) Ｎｒｆ２アクチベーターとしてのインダン
BR112019005416B1 (pt) Compostos antagonistas de trpv4, composição farmacêutica compreendendo os mesmos, processo para preparar a dita composição farmacêutica e usos terapêuticos dos compostos
BR112019005464B1 (pt) Compostos antagonistas de trpv4, composição farmacêutica compreendendo os mesmos, processo para preparar a dita composição farmacêutica e usos terapêuticos dos compostos

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200923

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20201228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210813

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220304